ASMB Assembly Biosciences Inc
Price (delayed)
$10.03
Market cap
$75.26M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$6.69
Enterprise value
$40M
Assembly Bio is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the
Highlights
ASMB's EPS has surged by 50% year-on-year and by 3.3% since the previous quarter
Assembly Biosciences's net income has increased by 34% YoY
ASMB's quick ratio is down by 30% year-on-year but it is up by 2.6% since the previous quarter
The equity has increased by 28% from the previous quarter but it has decreased by 19% YoY
The company's debt has surged by 114% QoQ and by 32% YoY
Key stats
What are the main financial stats of ASMB
Market
Valuations
Earnings
Shares outstanding
7.5M
Market cap
$75.26M
Enterprise value
$40M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.91
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$73.94M
Net income
-$40.18M
EBIT
-$39.85M
EBITDA
-$39.72M
Free cash flow
-$51.15M
Per share
Balance sheet
Liquidity
EPS
-$6.69
EPS diluted
-$6.69
Free cash flow per share
-$8.52
Book value per share
$5.25
Revenue per share
$0
TBVPS
$19.85
Total assets
$119.17M
Total liabilities
$85.81M
Debt
$3.09M
Equity
$33.36M
Working capital
$67.7M
Debt to equity
0.09
Current ratio
2.42
Quick ratio
2.34
Net debt/EBITDA
0.89
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-35.3%
Return on equity
-126.9%
Return on invested capital
-84.5%
Return on capital employed
-55.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ASMB stock price
How has the Assembly Biosciences stock price performed over time
Intraday
0.25%
1 week
18.56%
1 month
-5.29%
1 year
-22.37%
YTD
-36.44%
QTD
4.92%
Financial performance
How have Assembly Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$73.94M
Net income
-$40.18M
Gross margin
N/A
Net margin
N/A
Assembly Biosciences's net income has increased by 34% YoY
Assembly Biosciences's operating income has decreased by 3% YoY
Growth
What is Assembly Biosciences's growth rate over time
Valuation
What is Assembly Biosciences stock price valuation
P/E
N/A
P/B
1.91
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ASMB's EPS has surged by 50% year-on-year and by 3.3% since the previous quarter
The price to book (P/B) is 36% higher than the 5-year quarterly average of 1.4 but 32% lower than the last 4 quarters average of 2.8
The equity has increased by 28% from the previous quarter but it has decreased by 19% YoY
Efficiency
How efficient is Assembly Biosciences business performance
The company's return on assets has surged by 51% YoY but it fell by 2% QoQ
The ROIC has increased by 42% YoY but it has decreased by 22% from the previous quarter
The return on equity has declined by 8% year-on-year and by 4.4% since the previous quarter
Dividends
What is ASMB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ASMB.
Financial health
How did Assembly Biosciences financials performed over time
The total assets is 39% more than the total liabilities
ASMB's quick ratio is down by 30% year-on-year but it is up by 2.6% since the previous quarter
Assembly Biosciences's current ratio has decreased by 29% YoY but it has increased by 2.5% QoQ
The company's debt is 91% lower than its equity
The company's debt has surged by 114% QoQ and by 32% YoY
The debt to equity has soared by 50% from the previous quarter and by 50% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.